Instrument Inactif

Communiqués Hutchison China MediTech Limited London S.E.

Actions

KYG4672N1198

Produits pharmaceutiques

Communiqués

18/08	AstraZeneca - Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer	AQ
05/03	HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors	AQ
07/01	HUTCHMED China : English Presentation	PU
24/04/25	HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025	AQ
22/04/25	HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China	AQ
24/03/25	HUTCHMED Announces NMPA Conditional Approval for TAZVERIK for the Treatment of Relapsed or Refractory Follicular Lymphoma	AQ
20/03/25	HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025	AQ
06/03/25	HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China	AQ
14/01/25	HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	AQ
02/01/25	HUTCHMED China : Announces US$608 million Divestment of Non Core Joint Venture Form 6 K	PU
02/01/25	HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy	AQ
13/12/24	HUTCHMED China : to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) Form 6 K	PU
12/12/24	HUTCHMED China : Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy Form 6 K	PU
12/12/24	HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy	AQ
03/12/24	HUTCHMED China : and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Form 6 K	PU
29/11/24	HUTCHMED China : Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms Form 6 K	PU
22/11/24	HUTCHMED China : Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan Form 6 K	PU
22/11/24	HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan	AQ
20/11/24	HUTCHMED China : Announces Appointment of Independent Non executive Director and Member of Board Committee Form 6 K	PU
20/11/24	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee	AQ
06/11/24	HUTCHMED China : Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress Form 6 K	PU
06/11/24	HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress	AQ
31/10/24	HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda	AQ
16/10/24	HUTCHMED China : Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial Form 6 K	PU
16/10/24	HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial	AQ